Stingray Therapeutics, Inc.
Publicly observedHouston, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Houston | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Stingray Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | XNADTMZYJMP5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant14 Aug 2025Publicly observed
NIH SBIR/STTR award: A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab
USD 1,460,952.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant14 Aug 2025Publicly observed
NIH SBIR/STTR award: A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab
USD 1,460,952.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.